CoChat
Sign Up
Cited by 344

The DOI matches its Crossref record.

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Nakaoka, Yoshikazu, Isobe, Mitsuaki, Takei, Syuji, Tanaka, Yoshiya, Ishii, Tomonori, Yokota, Shumpei, Nomura, Akira, Yoshida, Seitaro, Nishimoto, Norihiro·2018·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2017-211878PMC PMC5867398
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2017-211878

Cites

Statistics

Figures

Figure 1 Kaplan-Meier curves showing time to relapse* in the intent-to-treat population (primary endpoint, A) and per-protocol set (sensitivity analysis, B) according to the protocol definition. *Two or more of five signs of relapse present: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, ischaemic symptoms. SC, subcutaneous; TCZ, tocilizumab.
Figure 1 Kaplan-Meier curves showing time to relapse* in the intent-to-treat population (primary endpoint, A) and per-protocol set (sensitivity analysis, B) according to the protocol definition. *Two or more of five signs of relapse present: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, ischaemic symptoms. SC, subcutaneous; TCZ, tocilizumab.CC BY-NC · PubMed Central
Figure 2 Forest plot showing the HR for each symptom in the protocol-based definition of relapse (intent-to-treat population). Data are based on Cox regression analysis and stratified by age (<18, 18–<65, ≥65 years). HRs and 95% CIs are shown in the plot. NE, not evaluable; SC, subcutaneous; TCZ, tocilizumab.
Figure 2 Forest plot showing the HR for each symptom in the protocol-based definition of relapse (intent-to-treat population). Data are based on Cox regression analysis and stratified by age (<18, 18–<65, ≥65 years). HRs and 95% CIs are shown in the plot. NE, not evaluable; SC, subcutaneous; TCZ, tocilizumab.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 39

  1. JCS Joint Working Group, 2011, Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society, Circ J, 75, 474, 10.1253/circj.CJ-88-0007 · DOI
  2. Hall, 1985, Takayasu arteritis. A study of 32 North American patients, Medicine, 64, 89, 10.1097/00005792-198503000-00002 · DOI
  3. Kerr, 1994, Takayasu arteritis, Ann Intern Med, 120, 919, 10.7326/0003-4819-120-11-199406010-00004 · DOI
  4. Watanabe, 2015, Current clinical features of new patients with takayasu arteritis observed from cross-country research in Japan: age and sex specificity, Circulation, 132, 1701, 10.1161/CIRCULATIONAHA.114.012547 · DOI
  5. Johnston, 2002, Takayasu arteritis: a review, J Clin Pathol, 55, 481, 10.1136/jcp.55.7.481 · DOI
  6. Brunner, 2010, Takayasu arteritis in children and adolescents, Rheumatology, 49, 1806, 10.1093/rheumatology/keq167 · DOI
  7. Noris, 1999, Interleukin-6 and rantes in takayasu arteritis: a guide for therapeutic decisions?, Circulation, 100, 55, 10.1161/01.CIR.100.1.55 · DOI
  8. Park, 2006, Serum cytokine profiles and their correlations with disease activity in takayasu's arteritis, Rheumatology, 45, 545, 10.1093/rheumatology/kei266 · DOI
  9. Alibaz-Oner, 2015, Serum cytokine profiles in Takayasu's arteritis: search for biomarkers, Clin Exp Rheumatol, 33, S-32
  10. Saadoun, 2015, Th1 and Th17 cytokines drive inflammation in takayasu arteritis, Arthritis Rheumatol, 67, 1353, 10.1002/art.39037 · DOI
  11. Kong, 2016, The critical role of IL-6 in the pathogenesis of takayasu arteritis, Clin Exp Rheumatol, 34, S21
  12. Koster, 2016, Recent advances in the clinical management of giant cell arteritis and takayasu arteritis, Curr Opin Rheumatol, 28, 211, 10.1097/BOR.0000000000000265 · DOI
  13. Hoffman, 1994, Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate, Arthritis Rheum, 37, 578, 10.1002/art.1780370420 · DOI
  14. Valsakumar, 2003, Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active takayasu's arteritis, J Rheumatol, 30, 1793
  15. Shinjo, 2007, Mycophenolate mofetil reduces disease activity and steroid dosage in takayasu arteritis, Clin Rheumatol, 26, 1871, 10.1007/s10067-007-0596-z · DOI
  16. Nakaoka, 2013, Tocilizumab for the treatment of patients with refractory takayasu arteritis, Int Heart J, 54, 405, 10.1536/ihj.54.405 · DOI
  17. Mekinian, 2012, Efficacy and tolerance of infliximab in refractory takayasu arteritis: French multicentre study, Rheumatology, 51, 882, 10.1093/rheumatology/ker380 · DOI
  18. Clifford, 2014, Recent advances in the medical management of takayasu arteritis: an update on use of biologic therapies, Curr Opin Rheumatol, 26, 7, 10.1097/BOR.0000000000000004 · DOI
  19. Mekinian, 2015, Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients, Circulation, 132, 1693, 10.1161/CIRCULATIONAHA.114.014321 · DOI
  20. Schmidt, 2012, Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup, Arthritis Care Res, 64, 1079, 10.1002/acr.21636 · DOI
  21. Nishimoto, 2008, Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody, Arthritis Rheum, 58, 1197, 10.1002/art.23373 · DOI
  22. Unizony, 2012, Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica, Arthritis Care Res, 64, 1720, 10.1002/acr.21750 · DOI
  23. Tombetti, 2013, Treatment of refractory takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center, J Rheumatol, 40, 2047, 10.3899/jrheum.130536 · DOI
  24. Abisror, 2013, Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review, Autoimmun Rev, 12, 1143, 10.1016/j.autrev.2013.06.019 · DOI
  25. Goel, 2013, Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of takayasu arteritis, Int J Rheum Dis, 16, 754, 10.1111/1756-185X.12220 · DOI
  26. Salvarani, 2012, Rescue treatment with tocilizumab for takayasu arteritis resistant to TNF-α blockers, Clin Exp Rheumatol, 30, S90
  27. Stubenrauch, 2010, Clin Ther, 32, 1597, 10.1016/j.clinthera.2010.07.021 · DOI
  28. Andrews, 2004, Non-invasive imaging in the diagnosis and management of takayasu's arteritis, Ann Rheum Dis, 63, 995, 10.1136/ard.2003.015701 · DOI
  29. Kato, 2015, Vessel wall inflammation of takayasu arteritis detected by contrast-enhanced magnetic resonance imaging: association with disease distribution and activity, PLoS One, 10, 10.1371/journal.pone.0145855 · DOI
  30. Misra, 2016, Increased circulating Th17 Cells, serum IL-17A, and IL-23 in takayasu arteritis, Autoimmune Dis, 2016, 1, 10.1155/2016/7841718 · DOI
  31. Villiger, 2016, Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 387, 1921, 10.1016/S0140-6736(16)00560-2 · DOI · Paper page
  32. Stone, 2017, Trial of tocilizumab in giant-cell arteritis, N Engl J Med, 377, 317, 10.1056/NEJMoa1613849 · DOI · Paper page
  33. Maksimowicz-McKinnon, 2009, Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?, Medicine, 88, 221, 10.1097/MD.0b013e3181af70c1 · DOI
  34. Manel, 2008, The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat, Nat Immunol, 9, 641, 10.1038/ni.1610 · DOI
  35. Nishimoto, 2008, Mechanisms and pathologic significances in increase in serum interleukin-6 (il-6) and soluble il-6 receptor after administration of an anti-il-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease, Blood, 112, 3959, 10.1182/blood-2008-05-155846 · DOI
  36. Nishimoto, 2010, Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions, Mod Rheumatol, 20, 222, 10.3109/s10165-010-0279-5 · DOI
  37. Koike, 2014, Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan, J Rheumatol, 41, 15, 10.3899/jrheum.130466 · DOI
  38. Listing, 2013, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, 52, 53, 10.1093/rheumatology/kes305 · DOI · Paper page
  39. Proven, 2003, Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes, Arthritis Rheum, 49, 703, 10.1002/art.11388 · DOI

Cited by

Sorted by citations

Metadata

Authors
Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., & Nishimoto, N.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2018-03
Volume
77
Issue
3
Pages
348-354
ISSN
0003-4967
DOI
10.1136/annrheumdis-2017-211878
PMC
PMC5867398
Cited by
344
References
0
Language
en
Licence
Funders
  • Chugai Pharmaceutical Co., Ltd.
  • F. Hoffmann-La Roche Ltd.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review